Sign In
to Vote &
Create Storyboards.
 
(Dana-Farber Cancer Institute) Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard